| Name | Title | Contact Details |
|---|
APER Solutions is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iCarbonX is building a digital life ecosystem by combining consumer life data, the Internet and artificial intelligence.
REP Fitness is a home and commercial equipment supplier that specializes in strength and conditioning equipment. No matter what space youre working out in, REP has you covered.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
DENTSPLY International is a leading manufacturer and distributor of dental and other consumable healthcare products. Our broad global product platform helps dental professionals serve patients` oral health care for a lifetime, from preventive services to tooth replacement. DENTSPLY oral health products range from general dental consumables and laboratory products to products supporting the dental specialty markets of orthodontics, endodontics and implants. Our powerful worldwide dental sales force takes our solutions to market around the globe. Now more than 2,800 members strong, our sales team keeps us close to the dental professionals who rely on our product solutions to serve their patients` complete oral health needs. DENTSPLY’s global consumable healthcare product team provides innovative urological and surgical solutions designed to improve the quality of life for users, caregivers, and practitioners. With a presence in more than 120 countries, patients and practitioners virtually everywhere in the world rely on DENTSPLY to deliver dental and healthcare solutions with a strong focus on quality, innovation, and service.